Please wait while the formulary information is being retrieved.
PIMECROLIMUS (pimecrolimus)
- Atopic dermatitis
- Intractable eczema
1 % topical cream
- Apply a thin layer to the affected area(s) by topical route 2 times per day ; rub in gently and completely
1 % topical cream
- Apply a thin layer to the affected area(s) by topical route 2 times per day ; rub in gently and completely
Atopic dermatitis
- Apply a thin layer to the affected area(s) by topical route 2 times per day ; rub in gently and completely
Intractable eczema
- Apply a thin layer to the affected area(s) by topical route 2 times per day ; rub in gently and completely
- None
Contraindicated
- None
Severe
Moderate
- None
- Malignant neoplasm of skin
Contraindicated
- Herpes simplex infection
- Herpes zoster
- Immunosuppression
- Lymphadenopathy
- Netherton's syndrome
- Pre-malignant skin lesion
Severe
Moderate
- None
PIMECROLIMUS (pimecrolimus)
- Atopic dermatitis
- Intractable eczema
- Bronchitis
- Fever
- Gastroenteritis
- Influenza
- Otitis externa
- Pharyngitis due to streptococcus pyogenes
- Skin and skin structure infection
- Tonsillitis
- Upper respiratory infection
- Viral infection
- Cough
- Diarrhea
- Folliculitis
- Headache disorder
- Pharyngitis
- Pruritus of skin
- Skin irritation
- Sore throat
- Treatment site sequelae
More Frequent
Severe
Less Severe
- Asthma
- Bacterial infection
- Chickenpox
- Dyspnea
- Herpes simplex infection
- Hypersensitivity drug reaction
- Lacerations
- Molluscum contagiosum infection
- Pneumonia
- Superficial ocular infection
- Urticaria
- Abdominal pain with cramps
- Acne vulgaris
- Acute bacterial otitis media
- Arthralgias
- Back pain
- Constipation
- Dysmenorrhea
- Epistaxis
- Erythema
- Impetigo
- Loose stools
- Nasal congestion
- Nausea
- Rhinorrhea
- Sinusitis
- Skin nodules
- Toothache
- Vomiting
- Wheezing
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Malignancy
Less Severe
- Dyschromia
Contraindicated
None
Severe Precaution
Pimecrolimus (Top)
Not approved age < 2 years. Possible increased risk of infections. Meta-analysis demonstrated no increase incidence of lymphoma with long term use in pediatric patients (BMC Pediatr. 2016; 16: 75.)
- 1 Day – 2 Years
- Not approved age < 2 years. Possible increased risk of infections. Meta-analysis demonstrated no increase incidence of lymphoma with long term use in pediatric patients (BMC Pediatr. 2016; 16: 75.)
Management or Monitoring Precaution
None
Pimecrolimus
- Severity Level:
C
- Additional Notes:
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Pimecrolimus
Insufficient data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- Patients have benefited from use of pimecrolimus when it is used correctly. Long-term safety for this drug is not known at this time. There have been rare reports of cancers (e.g., skin cancer, lymphoma) in patients using pimecrolimus.<br /><br />It is not known whether pimecrolimus caused these cancers when used on the skin. Further studies to determine the long-term safety of this product are ongoing. In the unlikely event that unusual lumps, swollen glands, or growths (especially on the skin) occur, contact your doctor right away.<br /><br /> The FDA recommends the following: This drug should be used only if other drugs have failed or if other medications are not considered appropriate by your doctor. Pimecrolimus should be used on the skin for short treatment periods only. If needed, treatment may be repeated with breaks in between.<br /><br />Use the smallest amount that will treat your condition properly, and apply only on the affected skin. Also, this medication should not be used in children younger than 2 years. As with all medications, discuss the risks, benefits, and proper use of this medication with your doctor.
| Atopic dermatitis | |
| L20 | Atopic dermatitis |
| L20.0 | Besnier's prurigo |
| L20.8 | Other atopic dermatitis |
| L20.81 | Atopic neurodermatitis |
| L20.82 | Flexural eczema |
| L20.84 | Intrinsic (allergic) eczema |
| L20.89 | Other atopic dermatitis |
| L20.9 | Atopic dermatitis, unspecified |
| Intractable eczema | |
| L20.82 | Flexural eczema |
| L20.84 | Intrinsic (allergic) eczema |
| 0-9 | A-Z |
|---|---|
| L20 | Atopic dermatitis |
| L20.0 | Besnier's prurigo |
| L20.8 | Other atopic dermatitis |
| L20.81 | Atopic neurodermatitis |
| L20.82 | Flexural eczema |
| L20.82 | Flexural eczema |
| L20.84 | Intrinsic (allergic) eczema |
| L20.84 | Intrinsic (allergic) eczema |
| L20.89 | Other atopic dermatitis |
| L20.9 | Atopic dermatitis, unspecified |
Formulary Reference Tool